Overview: ADAMTS13 Activity TestIntroduction: The ADAMTS13 Activity Test measures the activity of a protein involved in blood clotting to diagnose thrombotic thrombocytopenic purpura (TTP), a condition causing bruising, fatigue, or organ damage. Aligned with 2023 hematology guidelines, it uses a functional assay for high accuracy, aiding in confirming thrombotic disorders. This test is critical for guiding plasma exchange therapy, preventing organ damage, and improving outcomes in coagulation medicine.
Other Names: ADAMTS13 Test, Von Willebrand Factor-Cleaving Protease Assay.
FDA Status: Laboratory-developed test (LDT), meeting coagulation standards for diagnostic accuracy.
Historical Milestone: ADAMTS13 was linked to TTP in the 1990s. Functional assays emerged in the 2000s, and by the 2010s, standardized tests improved diagnostic reliability.
Purpose: Diagnoses TTP, guides therapy, and monitors disease in patients with bruising or organ dysfunction.
Test Parameters: 1. ADAMTS13 Activity
Pretest Condition: No fasting required. Collect plasma at symptom onset. Report bruising, fatigue, or medications (e.g., antiplatelets) affecting clotting.
Specimen: 2-4 mL plasma (sodium citrate tube). Centrifuge within 1 hour. Transport in a biohazard bag within 8 hours, preferably refrigerated.
Sample Stability at Room Temperature: 8 hours
Sample Stability at Refrigeration: 7 days
Sample Stability at Frozen: 6 months
Medical History: Document bruising, fatigue, organ dysfunction, or family history of thrombotic disorders. Include current medications affecting clotting.
Consent: Written consent required, explaining the test's purpose, diagnostic implications, and potential therapy needs.
Procedural Considerations: Uses a functional assay to measure ADAMTS13 activity. Results take 3-5 days due to assay complexity.
Factors Affecting Result Accuracy: Antiplatelet drugs or hemolysis may affect results. Improper storage can degrade samples. Timing of collection is critical during acute symptoms.
Clinical Significance: Low ADAMTS13 activity confirms TTP, prompting plasma exchange. Normal activity may require inhibitor testing to rule out autoimmune TTP.
Specialist Consultation: Consult a hematologist for result interpretation. Critical care referral is advised for severe cases.
Additional Supporting Tests: ADAMTS13 inhibitor assay, platelet count, or lactate dehydrogenase to confirm TTP or assess severity.
Test Limitations: False results may occur with improper sample handling. Non-TTP causes of thrombocytopenia require clinical correlation.
References: ASH TTP Guidelines, 2023; Zheng XL, Blood, 2022.
